TABLE I.

Study population characteristics

Demographic characteristics
Female sex, no. (%)	63 (44)
Age (y), median (range)	11 (5–17)
African American, no. (%)	131 (91)
Annual household income <$30,000, no. (%)	86 (64)
Public health insurance, no. (%)	122 (85)
Caregiver ≤ high school education, no. (%)	90 (63)
Clinical characteristics
Health care and medication use
ED visit, previous 12 mo, no. (%)	101 (70)
Controller medication use, no. (%)*	104 (72)
SABA use, days/2 weeks, mean (SD)	4.4 (5.2)
Lung function
FEV1/FVC (%), mean (SD)	80.7 (9.6)
Bronchodilator reversibility, no. (%)	34 (27)
Allergic sensitization
≥1 Positive SPT response, no. (%)	130 (90)
Cat, no. (%)	92 (64)
Cockroach, no. (%)	87 (60)
Dust mite, no. (%)	81 (56)
Mouse, no. (%)	74 (51)
Total IgE (kU/L), median (IQR)	189 (48–458)
Mouse-specific IgE (kU/L), median (IQR)	0.05 (0.05–10.3)
Cockroach-specific IgE (kU/L), median (IQR)	0.11 (0.03–1.23)
Allergen exposure, median (IQR)
Bed dust
Fel d 1 (μg/g)	1.5 (0.6–8.8)
Bla g 1 (U/g)	0.1 (0.1–1.7)
Der f 1 and Der p 1 (μg/g)	0.2 (0.04–0.8)
Mus m 1 (μg/g)	1.2 (0.3–3.7)
Bedroom floor dust
Fel d 1	0.4 (0.1–2.4)
Bla g 1 (U/g)	1.2 (0.1–12.5)
Der f 1 and Der p 1	0.1 (<LLOD-0.4)
Mus m 1	2.7 (0.4–10.7)

ED, Emergency department; IQR, interquartile range; LLOD, lower limit of detection; SABA, short-acting β-agonist.

^*Inhaled corticosteroid or leukotriene inhibitor.